Brokerages Expect Liquidia Technologies, Inc. (NASDAQ:LQDA) Will Post Earnings of -$0.37 Per Share

Wall Street brokerages predict that Liquidia Technologies, Inc. (NASDAQ:LQDA) will announce earnings of ($0.37) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Liquidia Technologies’ earnings. Liquidia Technologies posted earnings per share of ($0.72) during the same quarter last year, which indicates a positive year-over-year growth rate of 48.6%. The business is scheduled to announce its next earnings report on Wednesday, November 11th.

On average, analysts expect that Liquidia Technologies will report full-year earnings of ($1.69) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.65). For the next fiscal year, analysts forecast that the business will post earnings of ($1.13) per share, with EPS estimates ranging from ($1.61) to ($0.65). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Liquidia Technologies.

Liquidia Technologies (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.10).

A number of analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price target on shares of Liquidia Technologies in a research note on Tuesday, July 7th. Zacks Investment Research lowered shares of Liquidia Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Wedbush cut their target price on shares of Liquidia Technologies from $38.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, BidaskClub upgraded shares of Liquidia Technologies from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Liquidia Technologies has a consensus rating of “Buy” and an average target price of $22.44.

NASDAQ:LQDA traded down $0.13 on Friday, reaching $2.86. 1,213,729 shares of the company’s stock were exchanged, compared to its average volume of 286,885. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $107.97 million, a price-to-earnings ratio of -1.17 and a beta of 0.48. The business has a fifty day moving average of $4.96 and a 200-day moving average of $6.48. Liquidia Technologies has a 52-week low of $2.65 and a 52-week high of $12.10.

Several hedge funds have recently added to or reduced their stakes in LQDA. Jefferies Group LLC purchased a new position in Liquidia Technologies in the second quarter valued at approximately $15,788,000. Sofinnova Investments Inc. purchased a new position in Liquidia Technologies in the second quarter valued at approximately $6,736,000. Monashee Investment Management LLC purchased a new position in Liquidia Technologies in the second quarter valued at approximately $3,789,000. Opaleye Management Inc. purchased a new position in Liquidia Technologies in the second quarter valued at approximately $3,368,000. Finally, ArrowMark Colorado Holdings LLC increased its stake in Liquidia Technologies by 17.7% in the second quarter. ArrowMark Colorado Holdings LLC now owns 1,951,455 shares of the company’s stock valued at $16,431,000 after purchasing an additional 292,970 shares during the last quarter. Hedge funds and other institutional investors own 55.45% of the company’s stock.

About Liquidia Technologies

Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of novel products which utilize PRINT technology to transform the lives of patients. Its lead product candidate is LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials for the treatment of pulmonary arterial hypertension.

See Also: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Liquidia Technologies (LQDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Liquidia Technologies (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.